Form 4: Phathom Pharma Grants Equity to Chief Legal Officer

Phathom Pharmaceuticals' Chief Legal Officer, Anne Marie Cook, received grants of restricted stock units and stock options.

Summary

• Anne Marie Cook, Chief Legal Officer & Corporate Secretary of Phathom Pharmaceuticals, Inc., was granted 75,345 Restricted Stock Units (RSUs) on January 2, 2026.
• These RSUs vest in three equal annual installments, with 1/3 vesting on each of the first three anniversaries of January 2, 2026, contingent on continued service.
• Additionally, Cook was granted stock options to purchase 67,878 shares of common stock with an exercise price of $15.71 per share on January 2, 2026.
• These stock options vest monthly, with 1/48th of the total number of shares vesting each month following January 2, 2026, also contingent on continued service.
• Following these transactions, Cook beneficially owns 85,012 shares of common stock directly and 67,878 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The filing reports a routine grant of equity compensation to a key executive, which is generally viewed as a positive for aligning management interests with shareholders, but it does not contain information that would significantly alter the company's outlook.

Positives

• The Chief Legal Officer received a significant grant of 75,345 Restricted Stock Units (RSUs) and options for 67,878 shares, aligning her interests with long-term shareholder value.
• The equity grants serve as an incentive for continued service and performance, with vesting periods extending over multiple years.

Negatives

• No direct negatives are reported in this Form 4 filing.

Risks

• No specific risks are mentioned in this Form 4 filing, which primarily reports insider transactions.

Future Outlook

The vesting schedules for both the RSUs and stock options extend over several years (three years for RSUs, four years for stock options), indicating an expectation of continued service from the Chief Legal Officer and a long-term incentive structure.

Industry Context

The grant of restricted stock units and stock options to key executives is a standard practice in the pharmaceutical and biotechnology industries to attract, retain, and incentivize talent, aligning executive interests with long-term company performance and shareholder value.

Comparison to Industry Standards

• The use of RSUs and stock options as part of executive compensation is a common practice across publicly traded companies, including those in the pharmaceutical sector.
• The vesting schedules (3 years for RSUs, 4 years for options) are typical for long-term incentive plans designed to encourage executive retention and sustained performance.
• Specific comparable companies or projects are not detailed in this filing, as it focuses on an individual's transaction.

Stakeholder Impact

• Shareholders: The grants align the Chief Legal Officer's financial interests with long-term shareholder value, potentially encouraging decisions that benefit the company's stock performance.
• Employees: This is specific to one executive and does not directly impact the broader employee base, though it reflects the company's executive compensation strategy.

Next Steps

• Vesting of 1/3 of the RSUs on the first, second, and third anniversaries of January 2, 2026.
• Monthly vesting of 1/48th of the stock options following January 2, 2026.

Key Dates

Keywords

Phathom Pharmaceuticals, PHAT, Form 4, Anne Marie Cook, Restricted Stock Units, RSU, Stock Options, Executive Compensation, Insider Transaction, Equity Grant, Corporate Secretary, Chief Legal Officer